ClinicalTrials.gg

Program

GSK3862995B

A development code.

In GlaxoSmithKline's pipeline, Long acting anti-interleukin 33 (IL33) antibody. Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Bronchiectasis, led by GlaxoSmithKline.

Furthest: phase 2, since Sep 23, 20255 company-led studies, 4 open or runningNext primary completion: Dec 16, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline54 open or runningphase 2since Sep 23, 2025Nov 26, 2023Dec 16, 2026phase 1 · NCT06154837
  • Named in GlaxoSmithKline’s own pipeline as GSK3862995, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06154837 · 127 enrolled · United States, Germany, United Kingdom
  2. May 13, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06979518 · 30 enrolled · United States
  3. Sep 23, 2025Phase 2 study in BronchiectasisNCT07201051 · 363 planned · United States, Argentina, China and more
  4. Aug 24, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07789899 · 24 planned · United Kingdom
  5. Oct 29, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791 · 279 planned

Ahead

  1. Dec 16, 2026Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06154837
  2. May 4, 2027Primary completion: phase 2 study in BronchiectasisNCT07201051
  3. Sep 7, 2027Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07789899
  4. Mar 16, 2029Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791

TargetBeta

“Long acting anti-interleukin 33 (IL33) antibody”the company's pipeline, read by Claude · source

Other programs on IL33

ProgramCompanyFurthest phaseStudies
itepekimabruleSanofiphase 317
ompekimigPfizerphase 23
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07915791Pulmonary Disease, Chronic Obstructive2Not yet recruitingMar 16, 2029279
NCT07789899Pulmonary Disease, Chronic Obstructive · United Kingdom1RecruitingSep 7, 202724
NCT07201051Bronchiectasis · United States, Argentina, China and more2RecruitingMay 4, 2027363
NCT06979518Pulmonary Disease, Chronic Obstructive · United States1CompletedApr 22, 202630
NCT06154837Pulmonary Disease, Chronic Obstructive · United States, Germany, United Kingdom1Active, not recruitingDec 16, 2026127

How it is read

Names in the registry

  • “GSK3862995B”, 5 entries

Codes read as this program: GSK3862995B.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.